Table of Content



1 Relevant Concepts of Infliximab
1.1 Indications for Infliximab
1.2 Development of Infliximab in China
1.3 Governmental Approval of Infliximab in China
1.4 The Impact of COVID-19 on Infliximab sales in China


2 Sales of Infliximab in China, 2016-2020
2.1 Sales Value of Infliximab
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Infliximab
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Regions
2.3 Sales of Infliximab by Dosage Form in China, 2016-2020
2.3.1 Injection
2.3.2 Analysis of Other Dosage Forms


3 Analysis of Major Infliximab Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Infliximab Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Janssen Biologics BV
3.2.1 Enterprise Profile
3.2.2 Sales of REMICADE (Janssen’s Infliximab) in China


4 Prices of Infliximab for Different Manufacturers in China, 2020-2021
4.1 Janssen Biologics BV (REMICADE)


5 Prospect of Chinese Infliximab drug Market, 2021-2025
5.1 Influential Factors of Chinese Infliximab Market Development
5.1.1 The Impact of COVID-19 on Chinese Infliximab Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

List of Charts
Chart Patent Information About Infliximab Injection Registration in China
Chart Sales Value of Infliximab Injection over the World
Chart Sales Value of Infliximab Injection in China, 2016-2020
Chart Sales Value of Infliximab Injection in China by Regions, 2016-2020
Chart Sales Volume of Infliximab Injection in China, 2016-2020
Chart Sales Volume of Infliximab Injection in China by Regions, 2016-2020
Chart Market Share by Sales Value of Top Infliximab Manufacturers in China, 2016-2020
Chart Sales Value and Volume of REMICADE in China, 2016-2020
Chart Referential Prices of REMICADE in China, 2020-2021
Chart Forecast on Sales Value of Infliximab in China, 2021-2025
Chart Forecast on Sales Volume of Infliximab in China, 2021-2025